Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of SENSORION EO -,10
No Price
Closing Price XPAR 30.04.2026:
0,40 EUR
30.04.2026 15:35
Current Prices from SENSORION EO -,10
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
Paris
ALSEN.PA
EUR
30.04.2026 15:35
0,40 EUR
-
Quotrix
SSAAPE68.DUSD
EUR
30.04.2026 15:04
0,40 EUR
-
Düsseldorf
SSAAPE68.DUSB
EUR
30.04.2026 06:11
0,36 EUR
-
Share Float & Liquidity
Free Float86,64 %
Shares Float265,11 M
Shares Outstanding306 M
Company Profile for SENSORION EO -,10 Share
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
